CD105 as a Prognostic Marker in Liver Cancer
Author Information
Author(s): Yang Lian-yue, Lu Wei-qun, Huang Geng-wen, Wang Wei
Primary Institution: Xiangya Hospital, Central South University
Hypothesis
Can CD105 or CD34 serve as valid prognostic markers for postoperative recurrence and metastasis in hepatocellular carcinoma (HCC)?
Conclusion
CD105-MVD is a significant and independent prognostic factor for recurrence and metastasis in HCC patients.
Supporting Evidence
- CD105 was expressed in all HCC tissue specimens but not in normal liver tissue.
- CD105-MVD was significantly correlated with the 2-year overall survival rate.
- Multivariate analysis confirmed CD105-MVD as an independent prognostic factor.
Takeaway
This study found that a specific marker called CD105 can help doctors predict if liver cancer will come back after treatment.
Methodology
Immunohistochemical staining was performed on HCC tissue specimens to analyze CD105 and CD34 expression and their correlation with clinical outcomes.
Limitations
The study's findings need to be confirmed in larger cohorts with longer follow-up periods.
Participant Demographics
Patients aged 18 to 73 years, with a mean age of 44.4 years; 78 men and 35 women.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website